Characterization of critical reagents in ligand-binding assays: Enabling robust bioanalytical methods and lifecycle management

Bioanalysis

Volumn 5, Issue 2, 2013, Pages 227-244

  Geist, Brian J ^a   Egan, Adrienne Clements ^a   Yang, Tong Yuan ^a   Dong, Yuxin ^a   Shankar, Gopi ^a  

^a Biotechnology Center of Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C1414A; MONOCLONAL ANTIBODY C437A; REAGENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; BIOASSAY; CHEMICAL ANALYSIS; CHEMILUMINESCENCE IMMUNOASSAY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; LIFE CYCLE ASSESSMENT; LIGAND BINDING; LIGAND BINDING ASSAY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MATERIALS MANAGEMENT; MOLECULAR STABILITY; NONHUMAN; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCESS MONITORING; PROTEIN DETERMINATION; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; PROTEIN STABILITY; QUALITY CONTROL; REVIEW; TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

HUMANS; INDICATORS AND REAGENTS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PROTEINS; QUALITY CONTROL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872967092     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.304     Document Type: Review

References (52)

1. Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach Mw. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J. Biol. Chem. 3(4), 73-92 (2012).
2. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24(6), 274-280 (2006). (Pubitemid 43853075)
3. Lee JW, Kelley M. Quality assessment of bioanalytical quantification of monoclonal antibody drugs. Ther. Deliv. 2(3), 383-396 (2011).
4. Nowatzke WL, Rogers K, Wells E, Bowsher RR, Ray C, Unger S. Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. Bioanalysis 3(5), 509-521 (2011).
5. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 14(2), 296-302 (2012).
6. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011).
7. Desilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003). (Pubitemid 37449466)
8. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand-binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
9. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
10. O'hara DM, Theobald V, Egan AC et al. Ligand-binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J. 14(2), 316-328 (2012).
11. Staack RF, Stracke JO, Stubenrauch K, Vogel R, Schleypen J, Papadimitriou A. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. Bioanalysis 3(5), 523-534 (2011).
12. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol. 22(11), 1383-1391 (2004). (Pubitemid 39482857)
13. Stubenrauch K, Wessels U, Lenz H. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. J. Pharm. Biomed. Anal. 49(4), 1003-1008 (2009).
14. Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv. Drug Deliv. Rev. 58(5-6), 707-722 (2006). (Pubitemid 44255854)
15. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J. Pharm. Sci. 97(7), 2426-2447 (2008).
16. Sola RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J. Pharm. Sci. 98(4), 1223-1245 (2009).
17. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 3(6), 568-576 (2011).
18. Dubois M, Fenaille F, Clement G et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal. Chem. 80(5), 1737-1745 (2008). (Pubitemid 351429580)
19. Lu Q, Zheng X, Mcintosh T et al. Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Anal. Chem. 81(21), 8715-8723 (2009).
20. Li H, Ortiz R, Tran L et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267-1273 (2012).
21. Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom. Rev. 28(1), 147-176 (2009).
22. Kaltashov IA, Bobst CE, Abzalimov RR, Wang G, Baykal B, Wang S. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics. Biotechnol. Adv. 30(1), 210-222 (2012).
23. Ryan MH, Petrone D, Nemeth JF, Barnathan E, Bjorck L, Jordan RE. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol. Immunol. 45(7), 1837-1846 (2008).
24. Damen CW, Chen W, Chakraborty AB et al. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J. Am. Soc. Mass Spectrom. 20(11), 2021-2033 (2009).
25. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm. Res. 27(4), 544-575 (2010).
26. Gaza-Bulseco G, Liu H. Fragmentation of a recombinant monoclonal antibody at various pH. Pharm. Res. 25(8), 1881-1890 (2008).
27. Bertolotti-Ciarlet A, Wang W, Lownes R et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol. Immunol. 46(8-9), 1878-1882 (2009).
28. Gaza-Bulseco G, Faldu S, Hurkmans K, Chumsae C, Liu H. Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 870(1), 55-62 (2008).
29. Wei Z, Feng J, Lin HY et al. Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal. Chem. 79(7), 2797-2805 (2007). (Pubitemid 46595633)
30. Banks DD, Hambly DM, Scavezze JL, Siska CC, Stackhouse NL, Gadgil HS. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J. Pharm. Sci. 98(12), 4501-4510 (2009).
31. Goetze AM, Liu YD, Arroll T, Chu L, Flynn GC. Rates and impact of human antibody glycation in vivo. Glycobiology 22(2), 221-234 (2012).
32. Chelius D, Jing K, Lueras A et al. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal. Chem. 78(7), 2370-2376 (2006).
33. Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr. Pharm. Biotechnol. 9(6), 468-481 (2008).
34. Wang W, Nema S, Teagarden D. Protein aggregation-pathways and influencing factors. Int. J. Pharm. 390(2), 89-99 (2010).
35. Ejima D, Tsumoto K, Fukada H et al. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins 66(4), 954-962 (2007).
36. Sahin E, Grillo AO, Perkins MD, Roberts CJ. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J. Pharm. Sci. 99(12), 4830-4848 (2010).
37. Mason BD, Schoneich C, Kerwin BA. Effect of pH and light on aggregation and conformation of an IgG1 mAb. Mol. Pharm. 9(4), 774-790 (2012).
38. Den Engelsman J, Garidel P, Smulders R et al. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm. Res. 28(4), 920-933 (2011).
39. Paul R, Graff-Meyer A, Stahlberg H et al. Structure and function of purified monoclonal antibody dimers induced by different stress conditions. Pharm. Res. 29(8), 2047-2059 (2012).
40. Luo Q, Joubert MK, Stevenson R, Ketchem Rr, Narhi LO, Wypych J. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J. Biol. Chem. 286(28), 25134-25144 (2011).
41. Staub A, Guillarme D, Schappler J, Veuthey JL, Rudaz S. Intact protein analysis in the biopharmaceutical field. J. Pharm. Biomed. Anal. 55(4), 810-822 (2011).
42. Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell. Proteomics 9(8), 1716-1728 (2010).
43. Robinson NE. Protein deamidation. Proc. Natl Acad. Sci. USA 99(8), 5283-5288 (2002). (Pubitemid 34411540)
44. Zheng JY, Janis LJ. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int. J. Pharm. 308(1-2), 46-51 (2006). (Pubitemid 43097234)
45. Vlasak J, Bussat MC, Wang S et al. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal. Biochem. 392(2), 145-154 (2009).
46. Wakankar AA, Borchardt RT, Eigenbrot C et al. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry 46(6), 1534-1544 (2007).
47. Rehder DS, Chelius D, Mcauley A et al. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry 47(8), 2518-2530 (2008). (Pubitemid 351304557)
48. Beck A, Bussat MC, Zorn N et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 819(2), 203-218 (2005). (Pubitemid 40521956)
49. Franey H, Brych SR, Kolvenbach CG, Rajan RS. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci. 19(9), 1601-1615 (2010).
50. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 4(1), 17-23 (2012).
51. Cordoba AJ, Shyong BJ, Breen D, Harris RJ. Non-enzymatic hinge region fragmentation of antibodies in solution. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 818(2), 115-121 (2005). (Pubitemid 40331815)
52. Xie H, Chakraborty A, Ahn J et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2(4), (2010).